Kornimate/medical-research-clean huggingface dataset:
acupressure for the treatment of raynaud's phenomenon

Conditions: Primary Raynaud's Phenomeon

Summary: the use of acupressure will be compared to targeted raynaud's education and will evaluate the' frequency, duration and pain of raynaud's attacks.

using a raynaud's condition score, severity of tingling, numbness and pain of attacks, the number of attacks and patient and physician visual analog scale we will assess the effect of acupressure.

Eligibility criteria:
inclusion criteria: * \> 18 years old * have raynauds phenomenon, with at least 4 attacks in the last week * on stable medications * willing to attend study visits exclusion criteria: * smoker * have a history of stroke, heart attack or irregular heart rhythm * uncontrolled blood pressure * physical or mental illness that would interfere with participating in the study
changes in physical inactivity in patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: this is an objective cohort study using objective recording of physical activity (accelerometry) during and after the glaid intervention to investigate if a sedentary behavior change by participating in an 6-week physiotherapy-led exercise and education program (glaid) occurs. the glaid intervention is an education and exercise based intervention aiming at decreasing pain and improving function in patients with knee osteoarthritis. the primary outcome is change in objective recorded physical activity between baseline and follow-up.


Eligibility criteria:
inclusion criteria: * ≥40 years * diagnosed with knee oa * willing and able to complete study visits and procedures * owner of a smartphone or tablet * eligible for participation in the glaid treatment * speaks, reads and writes danish language exclusion criteria: * any condition, which in the opinion of the investigator, would put the subject at increased safety risk by participation, or otherwise make the subject unsuitable for this study.
ecoin for oab feasibility follow-on study

Conditions: Overactive Bladder; Urge Incontinence; Incontinence, Urinary; Urinary Urge Incontinence

Summary: this trial is a prospective, multicenter, single-arm follow-on study will evaluate the safety and effectiveness of ecointm tibial nerve stimulation in subjects with urgency urinary incontinence (uui) as defined by the american urological association (30). the follow-on study will evaluate changes from baseline in oab symptoms as measured by voiding diaries and patient-reported outcomes through 24 weeks of ecointm therapy (which is the same as 28 weeks from study device reimplantation).


Eligibility criteria:
inclusion criteria: 1. individual participated in the ecoin feasibility study for urgency urinary incontinence. 2. individual was implanted with the study device during the ecoin feasibility study for urgency urinary incontinence. exclusion criteria: 1. in the opinion of the investigator, individual is not a good candidate for participation in the study.
occupational therapy and surgery in carpometacarpal osteoarthritis

Conditions: Osteoarthritis in the Carpometacarpal (CMC) Joint

Summary: the purpose of the study is to investigate if occupational therapy may delay or prevent the need for surgery in patients with carpometacarpal(cmc) osteoarthritis (oa) who are scheduled for surgery in the cmc-joint. our study hypothesis is that compared to participants in the intervention group, significantly more participants in the control group have received cmc-surgery after two years.

hand osteoarthritis (oa) is one of the most prevalent musculoskeletal diseases in an adult population, and approximately 68% of people between the ages of 71 and 80 years have radiographic oa in the carpometacarpal (cmc) joint. currently, there is no cure for hand oa. however, several studies have demonstrated that hand exercises and cmc-orthoses may reduce pain and improve grip strength, and in a recent study, assistive devices improved activity performance and satisfaction with performance in people with hand-oa. still, most people do not receive any such treatment, but those with severe cmc-oa are often referred for surgery in this joint. the effect of occupational therapy to prevent or delay need for surgery cmc-oa has been investigated in a small study with 33 participants, but randomised controlled trails (rct) of good quality are needed.

Eligibility criteria:
inclusion criteria: * patients with cmc-oa who are referred for review for the need for surgery in the cmc joint. exclusion criteria: * persons with cognitive dysfunction * persons who do not understand the norwegian language * persons with other diseases or injuries that may negatively impact hand function

Keywords: hand osteoarthritis cmc1-joint surgery occupational therapy hand exercises assistive devices orthoses
arm cycling in facioscapulohumeral dystrophy (fshd) patients

Conditions: Facioscapulohumeral Muscular Dystrophy

Summary: the investigators believe that arm cycling has the potential to be effective in maintaining or improving shoulder muscle functioning. however, there is no evidence for its safety or effectiveness in the upper extremity. the aim of the study is to establish the ability of fshd sufferers to perform arm cycling to underpin the future design of an arm exercise trial. the study hypothesis is that the limited range of shoulder movement and muscle weakness should not impact the ability of fshd sufferers to perform arm cycling.


Eligibility criteria:
inclusion criteria: 1. aged 18-60 years 2. genetically confirmed diagnosis of fshd 3. willing to attend the assessment session 4. able to understand the participant information sheet and provide written informed consent exclusion criteria: 1. aged \ 60 years 2. co-morbidity that would affect their ability to perform arm cycling 3. unwilling to complete the assessments of the study 4. unable to understand the participant information sheet and provide written informed consent.
diabetic foot ulcers microbiome and pathogen identification

Conditions: Foot Ulcer; Diabetes Mellitus; Wound

Summary: this research is being done because people with diabetes have reduced healing capacity and prone to develop infections of foot wounds. this can be problematic because wounds that become infected may result in amputation and more severe complications. new evidence suggests that a better understanding of the microbiome of wounds (e.g., bacterial presence) may provide information about wound healing and provide an earlier opportunity to identify an individual who may be prone to develop diabetic foot infection in their wound. therefore, the purpose of this study is to evaluate the role of the microbiome of the diabetic foot ulcer in development of infection and wound healing. once the role of the microbiome is confirmed, progress towards the prevention and treatment of diabetic foot ulcers and complications may be possible.


Eligibility criteria:
inclusion criteria: * dfu patients with diabetes mellitus * have a hemoglobin a1c\[hba1c\] of 12% or less as measured within the last 6 months * stated willingness to comply with all study procedures and availability for the duration of the study exclusion criteria: * pregnant or lactating * uncontrolled blood glucose as demonstrated by by a hba1c of greater than 12% * bilateral wound or ulcer * current infection of coronavirus (covid-19) * unable to provide informed consent or are unwilling to participate.

Keywords: wound infection wound assessments wound's microbiome
stratagraft® skin tissue as an alternative to autografting full-thickness complex skin defects

Conditions: Trauma-related Wound; Burns; Skin Wound

Summary: about 20 participants will be enrolled in this trial if they have had an accident that damages both the dermal (outside) and epidermal (inside) layers of skin on up to 49% of their body. this condition is called full-thickness complex skin defects resulting from acute traumatic skin loss. participants will be treated with stratagraft skin tissue to evaluate it's safety and effectiveness for use in treating full-thickness complex skin defects.

the objective of this range-finding study was to assess the safety, tolerability, and efficacy of single or repeated application of stratagraft skin tissue in full-thickness complex skin defects resulting from acute traumatic skin loss (eg, thermal burns or degloving injuries) requiring surgical excision and autografting.

Eligibility criteria:
inclusion criteria: 1. men and women aged 18-65 years, inclusive 2. written informed consent 3. sufficient healthy skin identified and reserved as a donor site in the event that the stratagraft treatment site requires autografting 4. complex skin defects of up to 49% total body surface area (tbsa) requiring excision and autografting * total skin defect may consist of more than one wound area 5. full-thickness complex skin defects requiring excision and autografting 6. study treatment sites on the torso and limbs may be up to 200 cm2 in cohort 1 and 400 cm2 in cohort 2 7. for thermal burns only, first excision and grafting of treatment sites exclusion criteria: 1. pregnant women and prisoners 2. subjects receiving systemic immunosuppressive therapy 3. subjects with a known history of malignancy 4. preadmission insulin-dependent diabetic subjects 5. subjects with concurrent conditions that in the opinion of the investigator may compromise subject safety or study objectives 6. expected survival of less than three months 7. participation in the treatment group of an interventional study within the 90 days prior to enrollment 8. chronic wounds 9. the face, head, neck, hands, feet, buttocks, perineum, and area over joints 10. treatment sites with exposed tendon or bony prominences 11. chemical and electrical burns 12. treatment sites adjacent to unexcised eschar 13. clinical suspicion of infection at the anticipated treatment sites

Keywords: full-thickness acute trauma
long-term follow-up study of patients who received hlb-001 gene therapy

Conditions: Methylmalonic Acidemia

Summary: this is a non-interventional long-term follow-up study of patients who have participated in logicbio studies for the treatment of mma and received hlb-001

patients will be followed for a period of 15 years which includes the duration of time that the patient was in the treatment study.

Eligibility criteria:
inclusion criteria: * participant has previously participated in a logicbio clinical trial and received hlb-001. exclusion criteria: * none
gcf levels of chemokines in periodontitis

Conditions: Periodontal Diseases

Summary: this study aimed to determine ccl19/mip3beta(β) and ccl20/mip3alpha(α) in the gingival crevicular fluid (gcf) of the patients with different periodontitis phenotypes. a total of 72 individuals, 24 with stage iii grade b periodontitis (group 1), 24 with stage iii grade c periodontitis (group 2), and 24 periodontally healthy (control group) (group 3), were included in the study. gcf and clinical periodontal parameters were obtained at baseline. mip3β and mip3α levels in gcf were determined by elisa.


Eligibility criteria:
inclusion criteria: * have at least 20 natural teeth, excluding third molars. * periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (pd) ≥ 5 mm and clinical attachment level (cal) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting \>30% of the teeth, as detected on clinical and radiographical examinations. * periodontally healthy control group had no sign of gingival inflammation, no pd \> 3mm and no evidence of attachment or bone loss exclusion criteria: * history of systemic disease. * regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study. * periodontal treatment during last 6 months that could affect periodontal status. * smoking. * history of radiotherapy or chemotherapy. * current pregnancy, lactation or menopause.
a study of nivolumab safety and pharmacokinetics in patients with severe sepsis or septic shock.

Conditions: Severe Sepsis

Summary: a study to evaluate the safety, tolerability and pharmacokinetics of nivolumab in participants with severe sepsis or septic shock.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * men and women ages ≥ 18 years old * documented or suspected infection * severe sepsis or septic shock for at least 24 hours * sepsis-induced immunosuppression * in intensive care unit (icu) with no plans to discharge in next 24 hours exclusion criteria: * previous episode of severe sepsis or septic shock with icu admission during the current hospitalization * autoimmune disease * organ or bone marrow transplant * cancer treatment in the past 6 weeks * human immunodeficiency virus (hiv) infection and not on therapy prior to this episode of sepsis; hepatitis c virus(hcv) infection and still has virus (not cured); chronic hepatitis b virus (hbv) infection and not on treatment other protocol defined inclusion/exclusion criteria could apply
analysis of the evolution of suvmax by quantitative analysis method of bisphosphonate scintigraphy

Conditions: Cardiac Amyloidosis

Summary: recently, treatment with tafamidis in patients with cardiac attr lead to a significant reduction in mortality. the perugini score is commonly used on planar bone scans to differentiate cardiac attr from other amyloidosis or normal patients but fails to evaluate amyloid burden and patient prognosis. although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease.

cardiac amyloidosis is a cause of restrictive cardiomyopathy with preserved ejection fraction associated with amyloid fibrils deposits in the myocardium. two types of amyloid commonly infiltrate the heart: immunoglobulin light-chain amyloid (al), and transthyretin-related amyloid amyloidosis (attr). cardiac imaging is currently used for the diagnosis of attr, including planar scintigraphy with bone seeking radiopharmaceuticals, cardiac magnetic resonance and echocardiography with global longitudinal strain assessment.although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease.

Eligibility criteria:
inclusion criteria: * patient, male or female, over 18 years of age * patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy * patient with signed consent exclusion criteria: * patients with systemic al amyloidosis * protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision * pregnant or breastfeeding woman
clinical efficacy of respiratory pediatric physiotherapy on a child with hospital treated pneumonia

Conditions: Pneumonia Childhood; Rehabilitation; Recovery of Function

Summary: the accumulation of secretions in the bronchopulmonary air network promotes the detriment of respiratory functions generating hypoxia and causing a decrease in the cardiac output requiring the use of mechanical ventilation and hemodynamic support. it is intended to control the accumulation of secretions by means of respiratory pediatric physiotherapy (rpp) and to evaluate its effectiveness counting on biological plausibility.

the objective of this research protocol is to evaluate the effectiveness of rpp compared to postural drainage plus compression to the muscle belly of the upper limbs, as an adjuvant treatment for children with pneumonia. it is expected that the clinical severity decreases by 1.5 in the wang score (a modification of the silverman score), with a standard deviation of 2.6 points and a decrease of two days in the hospital stay with a α 0.05 in a one-tail test, a p of 80% and a 95.5% confidence interval.

Eligibility criteria:
inclusion criteria: 1. patients from the hospital infantil de méxico federico góme with diagnosis of pneumonia (considering the diagnostic criteria of the who and the guidelines for nosocomial pneumonia from the infectiology department. 2. patients aged 0 to 8 years old. 3. a minimum hs of 72 hours. 4. having informed consent. 5. not having had previous rpp treatment. exclusion criteria: 1. presenting a fever state for more than three days. performing physiotherapy increases the body's peripheral temperature. 2. presenting an oxygen saturation below 80%. 3. requiring mechanical ventilation. 4. hemodynamic instability. 5. presenting systemic inflammatory response syndrome. 6. inotropic support. 7. anatomical variants in the thorax. 8. unstable thorax. 9. esophageal atresia. 10. pleural effusion, pneumothorax. 11. alterations that compromise respiratory centers and/or the phrenic nerve. 12. neuromuscular diseases that compromise respiratory mechanics.

Keywords: pneumonia respiratory pediatric physiotherapy
evaluating the pharmacokinetics of novoeight® (turoctocog alfa) in relation to bmi in subjects with haemophilia a

Conditions: Congenital Bleeding Disorder; Haemophilia A

Summary: this trial is conducted globally. the aim of this trial is evaluating the pharmacokinetics (the exposure of the trial drug in the body) of novoeight® (turoctocog alfa) in relation to bmi (body mass index) in subjects with haemophilia a.


Eligibility criteria:
inclusion criteria: * male, age at least 18 years at the time of signing informed consent * history of more than 150 exposure days to any factor viii products * subjects with the diagnosis of congenital haemophilia a with factor viii activity below 1%, based on medical records exclusion criteria: * known history of factor viii inhibitors * inhibitors to factor viii (above or equal to 0.6 bu (bethesda units)) at screening measured by the nijmegen modified bethesda method * known congenital or acquired coagulation disorders other than haemophilia a * previous participation in pharmacokinetic sessions with turoctocog alfa in another trial
bupivacaine hydrochloride for pain control in cutaneous surgery

Conditions: Pain, Postoperative

Summary: the purpose of this study is to determine if the addition of bupivacaine hcl injections will improve pain control after skin surgery. this is a randomized clinical trial. approximately 100 participants will be randomized to receive either bupivacaine hcl or saline injections to help with the postsurgical pain. patients will be provided with a take-home journal to complete indicating when and how much pain medication they required for the 3 days immediately following surgery. participants will return the journal in-person at a follow up visit 7-21 days post-op. this study was a pilot study designed to determine the feasibility of this procedure. subjects currently living in the chicago metropolitan area and meet inclusion/exclusion criteria will be invited and considered for enrollment.


Eligibility criteria:
inclusion criteria: 1. \>18 years of age 2. receiving cutaneous surgery 3. in good general health as assessed by the investigator exclusion criteria: 1. participants with an allergy to bupivacaine or other amide anesthetics 2. participants unwilling to sign an irb approved consent form 3. participants with a contraindication to narcotic medication 4. participants who are pregnant or will become pregnant 5. participants who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function are not eligible
groin wound infection rate using prevena compared to standard dressing in vascular surgery patients with high risk

Conditions: Endovascular Procedures

Summary: evaluate wound healing using prevena compared to standard dressings in high risk patients after vascular surgery.

patients submitted to bilateral femoral endarterectomy will have one groin dressed with prevenatm and the contralateral one dressed with conventional bandage immediately after suture. both prevenatm and the conventional bandage at the contralateral side will be removed before the patient discharge. groin wound complications such as deep space infection, cutaneous cellulitis, dehiscence or re-interventions for wound-related complications will be observed in a 30-day evaluation window. this observation will be performed during the patient admission and in the post-operative standard of care visits among the first 30 days.

Eligibility criteria:
inclusion criteria: * patients with known bilateral vascular peripheral disease who are being evaluated for possible bilateral femoral endarterectomy * patients with one or more risk factor (diabetes mellitus, obesity, heavy smoker, immunodeficiency disease, groin reoperation, prosthetic) * patients in follow-up at clinic in the vascular surgery department * sign of informed consent * english speaking exclusion criteria: * refusal to participate * pregnancy * unilateral femoral endarterectomy * subjects for whom prevena ims is contraindicated
atypia of undetermined significance (aus) / follicular lesion of undetermined significance (flus)

Conditions: Diagnoses Disease

Summary: according to the guidelines for reporting thyroid fine needle aspirations known as the bethesda system, the category of atypical cells known as aus/ flus category has an estimated rate of 5 to 15% for malignancy. this study aims to determine the rate of malignancy of this category in our institution and to evaluate the clinical outcome of the participants.

this is a retrospective study that will help us to find out the rate of aus/ flus in our population of mississippi and the percentage of malignancies in these cases.the specimens will be searched through the university of mississippi medical center's pathology laboratory information system (copath), from april 2010 to december 2016. the retrospective cases will be retrieved using natural language search. the total number of thyroid fna will be retrieved and the percentage of cases with aus/ flus will be calculated. followup of these cases will be done looking for additional fine needle aspirations of the thyroid or thyroidectomy specimens. cases with diagnosis of aus/ flus will have correlation with the diagnosis on the thyroidectomy specimens if available in our system.

Eligibility criteria:
inclusion criteria: * thyroid fine needle aspirations interpreted as aus/ flus at university of mississippi medical center from april 2010 to december 2016. exclusion criteria: * fine needle aspirations of thyroid with diagnosis of unsatisfactory, benign, suspicious for follicular neoplasm/ follicular neoplasm, suspicious for malignancy and malignant.

Keywords: atypia, thyroid, malignancy